Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron vs. Ondansetron for CINV in Breast Cancer
NCT03606369Phase 3Unknown
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms). Primary endpoint: Acute nausea control at 24 hours. Status: unknown.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03606369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606369.